Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer

CONCLUSION: With excellent local control and tolerance, SBRT for omHSPC patients represents an attractive approach to defer systemic therapeutic escalation and prevent its side effects. Accurate patient selection for SBRT requires more data with longer follow-up and higher numbers of patients pending the results of upcoming randomized trials.PMID:37701481 | PMC:PMC10493250 | DOI:10.1016/j.ctro.2023.100673

Source: Clinical Prostate Cancer - September 13, 2023 Category: Cancer & Oncology Authors: D Baron D Pasquier T Pace-Loscos B Vandendorpe R Schiappa C Ortholan J M Hannoun-Levi Source Type: research